GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
X

Xuanzhu Biopharmaceutical Co 2575.HK · HKD

N/A · HKEX · 🇭🇰 Hong Kong

Compare

8.28

-1.08%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥56.1m

FY2019FY2025

Net income

−CN¥266.3m

FY2019FY2025

Free cash flow

−CN¥223.6m

FY2019FY2025

Shareholders' equity

CN¥1.53bn

FY2019FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
RevenueCN¥56.1mCN¥32.6mCN¥32,044————
Gross profitCN¥21.8m−CN¥12.6m−CN¥35.5m−CN¥30.2m———
Research and developmentCN¥120.3mCN¥180.9mCN¥238.7mCN¥444.9mCN¥429.6mCN¥234.8mCN¥345.4m
Operating income−CN¥253.1m−CN¥611.3m−CN¥374.7m−CN¥580.2m−CN¥565.5m−CN¥193.1m−CN¥404.9m
Net income−CN¥266.3m−CN¥603.3m−CN¥332.1m−CN¥595.7m−CN¥566.3m−CN¥192.9m−CN¥404.8m
Diluted earnings per share-0.56-1.34-0.64-1.33-1.09-0.37-0.78

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assetsCN¥1.83bnCN¥1.27bnCN¥1.45bnCN¥1.63bnCN¥2.30bnCN¥1.69bnCN¥708.5m
Cash and short-term investmentsCN¥765.4mCN¥294.1mCN¥495.1mCN¥793.0mCN¥1.51bnCN¥1.14bnCN¥137.4m
Total liabilitiesCN¥300.8mCN¥255.3mCN¥232.1mCN¥130.7mCN¥111.9mCN¥79.9mCN¥66.9m
DebtCN¥720,637CN¥1.6mCN¥18.8mCN¥32.8mCN¥36.0mCN¥48,573CN¥10.8m
Shareholders' equityCN¥1.53bnCN¥1.02bnCN¥1.22bnCN¥1.50bnCN¥2.18bnCN¥1.61bnCN¥641.6m
Shares outstanding479m451m518m449m518m518m518m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations−CN¥223.0m−CN¥104.7m−CN¥128.1m−CN¥449.1m−CN¥504.8m−CN¥246.6m−CN¥397.0m
Capital spending−CN¥622,518−CN¥548,614−CN¥1.9m−CN¥52.0m−CN¥93.2m−CN¥68.0m−CN¥145.9m
Free cash flow−CN¥223.6m−CN¥105.2m−CN¥130.0m−CN¥501.1m−CN¥598.0m−CN¥314.6m−CN¥543.0m
Dividends paid————−CN¥549,746−CN¥223,508−CN¥119,187

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥40.1mCN¥39.5mCN¥18.9mCN¥18.5mCN¥9.8mCN¥2.7mCN¥7.5mCN¥7.8m
Gross profitCN¥8.9mCN¥8.7mCN¥11.4mCN¥11.2mCN¥5.6m−CN¥5.1mCN¥4.2mCN¥4.4m
Operating income−CN¥45.1m−CN¥44.4m−CN¥62.4m−CN¥61.2m−CN¥60.2m−CN¥71.6m−CN¥241.9m−CN¥251.8m
Net income−CN¥43.5m−CN¥42.8m−CN¥74.9m−CN¥73.6m−CN¥60.8m−CN¥70.0m−CN¥237.0m−CN¥246.7m
Diluted earnings per share-0.08-0.08-0.16-0.15-0.13-0.15-0.53-0.55
Cash from operations−CN¥59.0m−CN¥58.0m−CN¥48.0m−CN¥47.0m−CN¥67.0m−CN¥70.0m−CN¥39.0m−CN¥41.0m
Total assetsCN¥1.79bnCN¥1.76bnCN¥1.82bnCN¥1.79bnCN¥1.17bnCN¥1.21bnCN¥1.27bnCN¥1.33bn
Cash and short-term investmentsCN¥587.3mCN¥578.0mCN¥725.6mCN¥713.0mCN¥120.3mCN¥216.6mCN¥294.1mCN¥272.5m
DebtCN¥251,798CN¥247,801CN¥719,787CN¥707,213CN¥1.1mCN¥902,303CN¥885,306CN¥921,631
Shareholders' equityCN¥1.50bnCN¥1.47bnCN¥1.52bnCN¥1.50bnCN¥926.8mCN¥956.2mCN¥1.02bnCN¥1.06bn

Financial ratios

Data as of 22 Sept 2026

FY2025FY2024FY2023FY2022
Gross margin38.8%-38.6%-110848.1%—
Operating margin-450.8%-1847.9%-1032406.2%—
Net margin-474.2%-1849.0%-1036451.2%—
Return on equity-17.4%-59.3%-27.2%-39.6%
Return on assets-14.6%-47.4%-22.8%-36.5%
Free cash flow yield-4.9%-2.7%——
Revenue growth72.1%101724.5%——
Earnings growth-55.9%81.6%-44.2%—
Current ratio3.75x2.06x3.79x8.55x
Debt to equity0.00x0.00x0.00x0.00x
Equity ratio83.5%80.0%84.0%92.0%
Interest coverage-1882.37x-1829.34x-256.55x-336.68x
R&D as a share of sales214.2%554.5%745046.0%—
Buybacks as a share of market value-14.9%———

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-24.2%5.6%—
Net income-23.5%6.7%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin10.4%———
Operating margin-973.7%———
Net margin-979.5%———

Valuation history

At each fiscal year end

FY2025
Price to earnings-109.7

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.